PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: PIPELINE ANALYSIS PART 07: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product VELCADE - Market size and forecast 2018-2023 KYPROLIS - Market size and forecast 2018-2023 NINLARO - Market size and forecast 2018-2023 Other products - Market size and forecast 2018-2023 Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES Market drivers Market challenges PART 12: MARKET TRENDS Expanded application Strategic alliances Special drug designations PART 13: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 14: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Allergan Plc Amgen Inc. Celgene Corp. Johnson & Johnson Services Inc. Takeda Pharmaceutical Co. Ltd. PART 15: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 16: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Global proteasome inhibitors market pipeline: Overview Exhibit 18: Global proteasome inhibitors market pipeline: Snapshot Exhibit 19: Product - Market share 2018-2023 (%) Exhibit 20: Comparison by product Exhibit 21: VELCADE - Market size and forecast 2018-2023 ($ millions) Exhibit 22: VELCADE - Year-over-year growth 2019-2023 (%) Exhibit 23: KYPROLIS - Market size and forecast 2018-2023 ($ millions) Exhibit 24: KYPROLIS - Year-over-year growth 2019-2023 (%) Exhibit 25: NINLARO - Market size and forecast 2018-2023 ($ millions) Exhibit 26: NINLARO - Year-over-year growth 2019-2023 (%) Exhibit 27: Other products - Market size and forecast 2018-2023 ($ millions) Exhibit 28: Other products - Year-over-year growth 2019-2023 (%) Exhibit 29: Market opportunity by product Exhibit 30: Customer landscape Exhibit 31: Market share by geography 2018-2023 (%) Exhibit 32: Geographic comparison Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 34: North America - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in North America Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Europe - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Europe Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 40: Asia - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in Asia Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 43: ROW - Year-over-year growth 2019-2023 (%) Exhibit 44: Top 3 countries in ROW Exhibit 45: Key leading countries Exhibit 46: Market opportunity Exhibit 47: Impact of drivers and challenges Exhibit 48: Vendor landscape Exhibit 49: Landscape disruption Exhibit 50: Vendors covered Exhibit 51: Vendor classification Exhibit 52: Market positioning of vendors Exhibit 53: Allergan Plc - Vendor overview Exhibit 54: Allergan Plc - Product segments Exhibit 55: Allergan Plc - Organizational developments Exhibit 56: Allergan Plc - Geographic focus Exhibit 57: Allergan Plc - Segment focus Exhibit 58: Allergan Plc - Key offerings Exhibit 59: Allergan Plc - Key customers Exhibit 60: Amgen Inc. - Vendor overview Exhibit 61: Amgen Inc. - Business segments Exhibit 62: Amgen Inc. - Organizational developments Exhibit 63: Amgen Inc. - Geographic focus Exhibit 64: Amgen Inc. - Key offerings Exhibit 65: Amgen Inc. - Key customers Exhibit 66: Celgene Corp. - Vendor overview Exhibit 67: Celgene Corp. - Business segments Exhibit 68: Celgene Corp. - Organizational developments Exhibit 69: Celgene Corp. - Geographic focus Exhibit 70: Celgene Corp. - Key offerings Exhibit 71: Celgene Corp. - Key customers Exhibit 72: Johnson & Johnson Services Inc. - Vendor overview Exhibit 73: Johnson & Johnson Services Inc. - Business segments Exhibit 74: Johnson & Johnson Services Inc. - Organizational developments Exhibit 75: Johnson & Johnson Services Inc. - Geographic focus Exhibit 76: Johnson & Johnson Services Inc. - Segment focus Exhibit 77: Johnson & Johnson Services Inc. - Key offerings Exhibit 78: Johnson & Johnson Services Inc. - Key customers Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Vendor overview Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Business segments Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Organizational developments Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Geographic focus Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Key customers Exhibit 85: Validation techniques employed for market sizing Exhibit 86: List of abbreviations Exhibit 87: Definition of market positioning of vendors

Allergan Plc, Amgen Inc., Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.